Skip to main content
ECBS 2022 - October
16 January 2023
WHO/BS/2022.2426 Rev: A Collaborative Study to Evaluate the Proposed 1st WHO International Standard for SARS-CoV-2 Antigen
WHO/BS/2022.2426 Rev: A Collaborative Study to Evaluate the Proposed 1st WHO International Standard for SARS-CoV-2 Antigen
19 July 2022
WHO/BS/2022.2427: Establishment of the 2nd WHO International Standard for anti-SARS-CoV-2 immunoglobulin and Reference Panel for antibodies to SARS-CoV-2 variants of concern
WHO/BS/2022.2427: Establishment of the 2nd WHO International Standard for anti-SARS-CoV-2 immunoglobulin and Reference Panel for antibodies to SARS-CoV-2 variants of concern
19 July 2022
WHO/BS/2022.2428: Collaborative Study to Evaluate Candidate 1st WHO International Standardsfor Antibodies to Human Papillomavirus Types 6,11, 31, 33, 45, 52 and 58
WHO/BS/2022.2428: Collaborative Study to Evaluate Candidate 1st WHO International Standardsfor Antibodies to Human Papillomavirus Types 6,11, 31, 33, 45, 52 and 58
21 December 2022
WHO/BS/2022.2429 Rev: Report on a collaborative study for Proposed Candidate 1st International Standard for the biological activities of Cetuximab
WHO/BS/2022.2429 Rev: Report on a collaborative study for Proposed Candidate 1st International Standard for the biological activities of Cetuximab
19 July 2022
WHO/BS/2022.2430: Proposed 1st WHO International Reference Panel for Infliximab anti-drug antibodies
WHO/BS/2022.2430: Proposed 1st WHO International Reference Panel for Infliximab anti-drug antibodies
19 July 2022
WHO/BS/2022.2431: Collaborative study: Calibration of 1st WHO Reference Reagent for Tetanus Antitoxin Equine for use in Flocculation Test
WHO/BS/2022.2431: Collaborative study: Calibration of 1st WHO Reference Reagent for Tetanus Antitoxin Equine for use in Flocculation Test
19 July 2022
WHO/BS/2022.2432: Report on the WHO collaborative study to establish Universal Reagents for
the D-Antigen potency testing of Inactivated Polio Vaccines
WHO/BS/2022.2432: Report on the WHO collaborative study to establish Universal Reagents for
the D-Antigen potency testing of Inactivated Polio Vaccines
19 July 2022
WHO/BS/2022.2434: Collaborative Study to Evaluate a Candidate World Health Organization International Standard for Antibodies to Chikungunya Virus
WHO/BS/2022.2434: Collaborative Study to Evaluate a Candidate World Health Organization International Standard for Antibodies to Chikungunya Virus
19 July 2022
WHO/BS/2022.2433: Report on a Collaborative Study for the Proposed WHO Reference Reagents for the Quantitation of Lentiviral Vector Integration Copy Numbers
WHO/BS/2022.2433: Report on a Collaborative Study for the Proposed WHO Reference Reagents for the Quantitation of Lentiviral Vector Integration Copy Numbers
19 July 2022
WHO/BS/2022.2435: Collaborative Study to Assess the Candidate 3rd International Standard for Rabies Immunoglobulin
WHO/BS/2022.2435: Collaborative Study to Assess the Candidate 3rd International Standard for Rabies Immunoglobulin
19 July 2022
WHO/BS/2022.2436: Proposed 2nd International Standard for Human Interleukin-6 (IL-6)
WHO/BS/2022.2436: Proposed 2nd International Standard for Human Interleukin-6 (IL-6)
2 September 2022
WHO/BS/2022.2437: WHO 2nd International Standard for Factor XIII, Plasma (20/292)
WHO/BS/2022.2437: WHO 2nd International Standard for Factor XIII, Plasma (20/292)
19 July 2022
WHO/BS/2022.2438: Report on the WHO collaborative study to investigate the utility of next generation sequencing (NGS) as a molecular test of virus stocks used in the manufacture of Type 1 and 2 Poliovirus vaccine (Oral)
WHO/BS/2022.2438: Report on the WHO collaborative study to investigate the utility of next generation sequencing (NGS) as a molecular test of virus stocks used in the manufacture of Type 1 and 2 Poliovirus vaccine (Oral)
19 July 2022
WHO/BS/2022.2439: Requests to initiate new WHO reference material projects for biologicals
WHO/BS/2022.2439: Requests to initiate new WHO reference material projects for biologicals
ECBS 2022 - April
